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MRI  Magnetic resonance imaging 
mRNA Messenger ribonucleic acid 
MS  Multiple sclerosis 
msec  Milliseconds 
NEJ  Newly excysted juvenile 
NET  Neutrophil extracellular trap 
ng  Nanograms 
NK  Natural killer cells 
nm  Nanometre 
NOD  Non-obese diabetic (mice) 
OD  Optical density 
O/N  Overnight 
Ova  Ovalbumin 
Ov-HDM Opisthorchis viverrini helminth defence molecule 
PI  Peak I 
PII  Peak II 
PC  Phosphorylcholine 
PMA  Phorbol myristate acetate 
Poly (I:C) Polyinosinic:polycytidylic acid 
PPAR  Peroxisome proliferator activated receptor 
PSMβ1 Proteasome subunit, beta type1 
qRT-PCR Quantitative reverse transcriptase polymerase chain reaction 
RA  Rhematoid arthritis 
Relm-α Resistin-like molecule alpha 
RNA  Ribonucleic acid 
 
 
xxi 
 
ROS  Reactive oxygen species 
RRMS Relapsing-remitting multiple sclerosis 
RT  Room temperature 
RXR  Retinoid X receptor 
SEA  Soluble egg antigens 
sec  Seconds 
SEM  Standard error of mean  
SLE  Systemic lupus erythematous  
SNP  Single nucleotide polymorphisms 
SUMO  Small ubiquitin-like modifier proteins 
SPMS  Secondary progressive multiple sclerosis 
sup  Supernatant 
SSC-A  Side scatter profile   
TGF-β  Transforming growth factor-beta 
Th1  T-helper 1 
Th2  T-helper 2  
Th17  T-helper 17 
TID  Type 1 diabetes 
TIM-3  T cell immunoglobulin domain and mucin domain-3 
TLR  Toll-like receptor 
TNBS  Trinitrobenzene sulfonic acid 
TNF  Tumour necrosis factor 
Treg  T-regulatory 
uPA  urokinase-type plasminogen activator 
vATPase  Vacuolar ATPase 
v/v  Volume/volume 
x g  Relative centrifugal force 
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Abstract 
 
Parasitic worms (helminths) have evolved mechanisms to potently modulate the 
mammalian immune response to ensure their long-term survival, while concomitantly 
preventing excessive tissue pathology within the host. The outcome of this activity is a 
potent suppression of mammalian pro-inflammatory Th1 and Th17 immune responses. 
This immune-modulatory phenomenon is attributable to the molecules 
excreted/secreted by helminths as they migrate through their human hosts. The 
identification of these molecules has the potential to contribute to the development of 
novel therapeutics for the treatment of autoimmune diseases as these diseases are 
mediated by pro-inflammatory Th1 and Th17 immune responses.  
 
It has previously been shown that the delivery of a single peptide, FhHDM-1, which is 
excreted/secreted from the helminth, Fasciola hepatica, prevented the development of 
murine type 1 diabetes and multiple sclerosis. The aetiological similarity between these 
two diseases, is the establishment of the pro-inflammatory environment by 
macrophages and neutrophils. Therefore, it was hypothesised that FhHDM-1 likely 
mediated its protective effect through anti-inflammatory mechanisms directed at these 
cells. In this study, it was confirmed that FhHDM-1, specifically interacted with both 
murine and human neutrophils and macrophages. Furthermore, it was demonstrated that 
FhHDM-1 modulated the activity of these cells, by inhibiting the secretion of pro-
inflammatory cytokines/chemokines, which, in turn, prevented further activation of 
pro-inflammatory T cells and dendritic cells.  
 
The use of transcriptional profiling revealed that, of the 41,436 genes analysed in 
macrophages, treatment with FhHDM-1 altered the expression levels of only 6 of these. 
Of these, only the expression level of SerpinB2 was increased, and this was shown to 
subsequently mediate the suppression of pro-inflammatory cytokine secretion by T 
cells. In the context of an inflammatory stimulus, FhHDM-1 regulated the expression 
of numerous pro-inflammatory genes in macrophages. Pathway analysis predicted that 
this anti-inflammatory activity was mediated through the activation of PPAR-γ 
pathways. This is the first report of a PPAR-γ agonist being secreted by a helminth 
parasite as a mechanism of modulating mammalian innate immune responses. 
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Importantly, a homologous parasite peptide from a related trematode parasite 
demonstrated the same activity suggesting a conserved mechanism of action among 
parasite helminths.  
 
Analysis of the sequence of the FhHDM-1 peptide, combined with immunological 
assays of peptide derivatives, supported the discovery of the minimally active sequence, 
FhHDM-1.C2. This peptide contained both the amphipathic C-terminus region, 
previously identified as functional, and a sequence of 5 amino acids (KARDR), which 
was newly identified as essential for the binding and internal localisation of FhHDM-
1. This C2 derivative mimicked the activity of the full length peptide in every way, such 
as the ability to bind and be internalised by macrophages, to increase macrophage 
lysosomal pH, to induce the expression of SerpinB2, and to inhibit the production of 
pro-inflammatory cytokines. 
 
In summary, this thesis has newly identified the binding and active domains of the 
parasite immune-modulatory peptide, FhHDM-1, and discovered the novel 
mechanisms by which the peptide regulates pro-inflammatory innate immune responses. 
Combined, these findings have significantly advanced the progress towards translation 
of the FhHDM-1 peptide for therapeutic use in immune-mediated diseases. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
